Masthead

Clinic Offers Novel Therapies for Inflammatory Breast Cancer Patients

| Comments (0)

By Danielle Walsh, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic

The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic at MD Anderson is the first of its kind to focus on patients with inflammatory breast cancer (IBC). Since opening in October 2007, we've seen more than 300 IBC patients from across the country.

IBC.jpgTreating IBC requires the coordinated efforts of every member of the oncology team. Our multidisciplinary team of experts in medical oncology, surgical oncology, radiation oncology, diagnostic radiology, pathology and IBC biology are passionate and committed to fighting IBC.

The team of breast medical oncologists dedicated to IBC includes Naoto Ueno, M.D., Ph.D., Vicente Valero, M.D., and Ricardo Alvarez, M.D. They are further supported by advanced practice nurse Pam Alizadeh, who is available to see patients every day. 

Rounding out our team are radiologists Thomas Buchholz, M.D., and Wendy Woodward, M.D., diagnostic radiologist Wei Yang, M.D., and surgeons Anthony Lucci, M.D., and Gildy Babiera, M.D.

Breast Medical Oncology, considers it "a great honor and pleasure to direct the IBC clinical research with this highly motivated multidisciplinary team of professionals. As virulent as this disease is, the inflammatory breast cancer team responds with as much vigor and dedication to understand the biology of the disease and to develop novel therapies with the goal of eradicating IBC."

Unique to the Morgan Welch IBC Clinic is our IBC-specific and IBC-inclusive clinical trial portfolio available to patients. We lead the international IBC registry that collects epidemiological, pathological and historical information, as well as blood and tissue samples for future studies. We also offer a number of clinical trials investigating novel therapeutics in IBC.

Currently, we are enrolling patients in several IBC-specific clinical trials:
In addition, we understand the importance of pushing the envelope for IBC patients with tumors that don't respond completely to chemotherapy or with focused metastatic disease, and offer trials open to IBC patients. A number of protocols are under development and will be available for patient enrollment soon. 
  • A Phase II Study of TKI258 (Dovitinib Lactate) as Salvage Therapy in Patients with Stage IV HER2-negative IBC and Local or Distant Relapse (Ricardo Alvarez, M.D., Principal Investigator)
  • A Phase I/II Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of KW-2450 in Combination With Lapatinib and Letrozole in Subjects With Advanced or Metastatic Breast Cancer Whose Tumor Overexpresses HER2 (Naoto Ueno, M.D., Ph.D., Principal Investigator)
  • A Phase I/II Study of Entinostat and Lapatinib in Patients With HER2-positive Metastatic Breast Cancer in Women Where Trastuzumab Has Failed
  • A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens With Weekly Paclitaxel and Neratinib or Trastuzumab Followed by Doxorubicin and Cyclophosphamide With Postoperative Trastuzumab in Women With Locally Advanced HER2 Positive Breast C
  • A Phase II Study of Combination Chemotherapy of Ixabepilone, Capecitabine, and Bevacizumab for Patients With Inflammatory and Locally Advanced Breast Cancer, HER-2 Negative, Who Remain Non-Surgical Candidates After Neoadjuvant Treatment With Taxane and Anthracycline-Based Chemotherapy
For women with IBC, finding a medical team experienced in treating the rare disease is paramount. The Morgan Welch IBC Clinic and Research Program allows IBC patients to receive state-of-the-art treatment from a dedicated team of multidisciplinary professionals, while also contributing to the understanding of the disease through participation in protocol-based research.br />If you would like more information about these clinical studies or other treatment options, please e-mail the IBC Research Program at ibcp@mdanderson.org or visit the Inflammatory Breast Cancer Clinic website. For patient referrals, call 713-792-4124 or 1-877-MDA-6789.

Leave a comment

Search

Connect on social media

Sign In

Archives